Note for guidance. Production and quality control of cytokine products derived by biotechnological processes. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
出版信息
Biologicals. 1991 Apr;19(2):125-31.
PMID:1888491
Abstract
摘要
相似文献
1
2
3
4
Note for guidance. Guidelines for minimizing the risk of transmitting agents causing spongiform encephalopathy via medicinal products. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
Biologicals. 1992 Jun;20(2):155-8.
5
6
European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
Dev Biol (Basel). 2000;104:53-6.
7
EEC note for guidance: production and quality control of cytokine products derived by biotechnological processes. AD hoc Working Party on Biotechnology/Pharmacy.
Pharmacol Toxicol. 1990 Oct;67(4):353-8. doi: 10.1111/j.1600-0773.1990.tb00845.x.
8
Virus validation procedures: practical aspects.
Blood Coagul Fibrinolysis. 1995 Jul;6 Suppl 2:S10-2.
9
Notes to applicants for marketing authorizations on the production and quality control of monoclonal antibodies of murine origin intended for use in man. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy.
J Biol Stand. 1989 Jul;17(3):213-22. doi: 10.1016/0092-1157(89)90013-9.
10
Notes to applicants for marketing authorizations on the pre-clinical biological safety testing of medicinal products derived from biotechnology (and comparable products derived from chemical synthesis). Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines.
J Biol Stand. 1989 Jul;17(3):203-12. doi: 10.1016/0092-1157(89)90012-7.
引用本文的文献
1
[Basics of the pharmacology of biopharmaceuticals].
Hautarzt. 2019 Dec;70(12):926-933. doi: 10.1007/s00105-019-04502-4.
Zotero 插件